AG-946
A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
Arms / Cohorts
Experimental, Core Period: Phase 2a:2a: Tebapivat (AG-946) 5 mg
Accepting patients
Experimental, Core Period: Phase 2b:2b: Tebapivat (AG-946) 10mg
Accepting patients
Experimental, Core Period: Phase 2b:2b: Tebapivat (AG-946) 15 mg
Accepting patients
Experimental, Core Period: Phase 2b:2b: Tebapivat (AG-946) 20 mg
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.